Mandate

Vinge advises Hansa Medical in connection with a directed share issue

November 15, 2018

The board of directors of Hansa Medical has resolved on a directed new issue of shares, whereby Hansa Medical will raise proceeds of approximately SEK 453 / USD 50 million, before issue costs.

The share issue is directed to a number of selected international and Swedish reputable investors and life sciences specialist investors, on the basis of an accelerated bookbuilding process conducted by Cowen, RBC Capital Markets and Skandinaviska Enskilda Banken.

Hansa Medical is a biopharmaceutical company developing novel immunomodulatory enzymes for organ transplantation and acute autoimmune diseases. The company’s lead product, imlifidase, is a proprietary antibody-degrading enzyme in late-stage clinical development for kidney transplant patients and has significant potential for further development in other solid organ transplantation and in acute autoimmune indications.

Vinge’s team has consisted of Dain Hård Nevonen, Erik Sjöman, Joakim Hagberg and Edin Agic. 
 

Related news

Sanctions update December (part 2)

Further to our previous sanctions newsletters we herewith inform about recent sanctions developments, following the Council’s adoption of the ninth sanction package on 16 December 2022, and an agreement as to a price cap on Russian gas.
December 30, 2022

COP27 – one step closer to climate justice

COP27 was concluded on 18 November 2022 after two weeks of negotiations in Sharm El Sheikh in Egypt with the presence of leaders and representatives from 190 countries. The 1.5 °C target was a priority item on the agenda ahead of COP27, along with the efforts to support developing countries, which are particularly vulnerable to the effects of climate change. Amongst the EU’s top priorities ahead of the conference were to accelerate the phase out of coal, as well as to abolish inefficient fossil fuel subsidies.
December 19, 2022

Sanctions update December 2022

Further to our previous sanctions newsletters we herewith inform about recent sanctions developments as follows.
December 14, 2022